Smart Onc Studio

Dr Neil J. Shah & Dr Matthew Dallos

Conversations for oncology teams, from the people treating patients today Hosted by Dr. Neil J. Shah and Dr. Matthew Dallos, SmartOnc Studio breaks down emerging data, next-generation therapies, and toxicity management pearls into practical takeaways for real-world practice.

Episodes

  1. 23 Oct

    Managing IO-TKI Toxicity in Kidney Cancer with Dr. Maria Carlo

    In this episode of SmartOnc Studio, hosts Dr. Matt Dallos and Dr. Neil Shah talk with oncologist Dr. Maria Carlo of Memorial Sloan Kettering Cancer Center, whose clinic is devoted entirely to kidney cancer. Their conversation focuses on renal cancer patients, and Dr. Carlo dives into treatments like IO-TKI therapy and immunotherapy and how drug half-life changes the way she counsels patients.  Their conversation begins with the four first-line options for advanced renal cell carcinoma and how she decides which kind of treatment to administer. She gives listeners a hands-on walk-through of toxicity management. The second half is all about hypertensive patients. Dr. Carlo covers when to call in the specialist, how to tell TKI diarrhea from immune-related colitis, and why vedolizumab has made rechallenging with immunotherapy far more common at her institution. She also discusses hand-foot syndrome, mucositis, fatigue, and what to expect when on cabozantinib and lenvatinib. To close, she offers listeners some grounding advice: Keep the lines of communication wide open and talk about dosage, life events, and how you’re feeling. What You'll Discover in This Episode: 01:25 — The four first-line regimens for advanced kidney cancer, the IO-IO versus IO-TKI branch point, and how half-life shapes patient counseling 05:32 — Managing hypertension on TKIs, including blood pressure thresholds for starting treatment, home monitoring, and when to bring in a cardiologist or nephrologist 11:03 — Sorting out diarrhea on IO-TKI therapy, from the first phone call to GI PCR panels, fecal calprotectin, sigmoidoscopy, and vedolizumab 17:46— Hand-foot syndrome, mucositis, voice changes, and hair depigmentation, plus simple prevention steps patients can take at home 29:04 — How to hold TKIs around surgery, dental procedures, and radiation, and where better data is still needed Let's Connect Smart Onc Studio Dr. Neil Shah  Dr. Matt Dallos  Dr. Maria Carlo

  2. 24 Sept

    The Godfather of EV/Pembro: Dr. Jonathan Rosenberg on Bladder Cancer's Biggest Breakthrough

    In this episode of SmartOnc Studio, hosts Dr. Neil Shah and Dr. Matt Dallos sit down with Dr. Jonathan Rosenberg, Chief of the GU Medical Oncology Service at Memorial Sloan Kettering Cancer Center. He led the early-phase trials that brought enfortumab vedotin plus pembrolizumab (EV + Pembro) into practice, and this conversation covers how that regimen actually works, why it changed the standard of care, and what it takes to manage patients on it day to day. The first half of the episode walks through the science: how the antibody-drug conjugate targets nectin-4, and how the pivotal trials produced results strong enough to reshape treatment guidelines. The second half gets practical. Dr. Rosenberg breaks down the regimen's signature toxicities, including skin rash, hyperglycemia, peripheral neuropathy, and eye problems, and explains how he decides when to dose reduce, hold treatment, or push through. What You'll Discover in This Episode: 01:16 — How enfortumab vedotin and pembrolizumab work together. The nectin-4 mechanism, the ADC design, and the early trials that led to approval 05:24 — EV-302, the phase 3 trial that nearly doubled survival for metastatic urothelial cancer and reset the first-line standard of care 07:32 — Moving into the perioperative setting. EV-303 and EV-304 (KEYNOTE-905) in muscle-invasive bladder cancer, and the ongoing debate over three cycles versus four 12:55 — Managing toxicity. What skin rash, hyperglycemia, peripheral neuropathy, and eye side effects actually look like, and when each one tends to show up 25:40 — Handling real-world situations like surgery, dental work, and radiation while a patient is on treatment, plus Dr. Rosenberg's top takeaways for clinicians Let's Connect Smart Onc Studio Dr. Neil Shah  Dr. Matt Dallos  Dr. Jonathan Rosenberg

  • 2 Episodes

About

Conversations for oncology teams, from the people treating patients today Hosted by Dr. Neil J. Shah and Dr. Matthew Dallos, SmartOnc Studio breaks down emerging data, next-generation therapies, and toxicity management pearls into practical takeaways for real-world practice.

Information

  • Creator
    Dr Neil J. Shah & Dr Matthew Dallos
  • Years Active
    2026
  • Episodes
    2
  • Rating
    Clean
  • Copyright
    © Dr Neil J. Shah & Dr Matthew Dallos
  • Show Website
    Smart Onc Studio

You Might Also Like